- Home
- ONC
ONC
BeiGene Ltd. American Depositary Shares
as 03-28-2025 4:00pm EST
| Founded: | 2010 | Country: | Cayman Islands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 19.3B | IPO Year: | N/A |
| Target Price: | $330.50 | AVG Volume (30 days): | 499.8K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $126.97 - $287.88 | Next Earning Date: | 05-07-2025 |
| Revenue: | $3,810,241,000 | Revenue Growth: | 54.97% |
| Revenue Growth (this year): | 856.26% | Revenue Growth (next year): | 19.78% |
Latest BeiGene Ltd. American Depositary Shares News
ONC Breaking Stock News: Dive into ONC Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Exploring 3 High Growth Tech Stocks In The US Market
Benzinga
12 days ago
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
MT Newswires
24 days ago
Beigene Insider Sold Shares Worth $2,073,826, According to a Recent SEC Filing
Thomson Reuters StreetEvents
24 days ago
Q4 2024 Zymeworks Inc Earnings Call
MT Newswires
25 days ago
Beigene Insider Sold Shares Worth $24,674,638, According to a Recent SEC Filing
Simply Wall St.
25 days ago
FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction
Pharmaceutical Technology
25 days ago
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
MT Newswires
a month ago
BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment
Compare ONC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ONC BeiGene Ltd. American Depositary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.